Drug Type Small molecule drug |
Synonyms Adomeglivant (USAN), 74Z5ZL2KVG, LY-2409021 + [1] |
Target |
Action antagonists |
Mechanism GCGR antagonists(Glucagon receptor antagonists) |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC32H36F3NO4 |
InChIKeyFASLTMSUPQDLIB-MHZLTWQESA-N |
CAS Registry1488363-78-5 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus, Type 2 | Phase 2 | United States | 01 Mar 2009 | |
Diabetes Mellitus, Type 2 | Phase 2 | Germany | 01 Mar 2009 | |
Diabetes Mellitus, Type 2 | Phase 2 | Lithuania | 01 Mar 2009 | |
Kidney Failure, Chronic | Phase 1 | Germany | 01 Aug 2013 | |
Kidney Failure, Chronic | Phase 1 | United Kingdom | 01 Aug 2013 | |
Diabetes Mellitus, Type 1 | Phase 1 | Germany | 01 Jul 2012 |
Not Applicable | FGF21 | - | glucagon receptor antagonist (Pancreatectomized subjects) | xepcpzmsmf(lfhstnueqe) = qhuzgskvfw ztvourcqnj (ywnjsozazn ) | Positive | 03 Oct 2023 | |
glucagon receptor antagonist (Control subjects) | xepcpzmsmf(lfhstnueqe) = iovcgchgar ztvourcqnj (ywnjsozazn ) | ||||||
Phase 1 | - | 35 | (LY2409021 Cohort 1 (Test-Medium Tablet Fasted)) | ktubcjxzfh(tgufcnlmbw) = oqvclawqmh nftsrivbqr (ixzreogflj, 20) View more | - | 11 Mar 2019 | |
(LY2409021 Cohort 1 (Reference Capsules Fasted)) | ktubcjxzfh(tgufcnlmbw) = ibugrdwhpm nftsrivbqr (ixzreogflj, 38) View more | ||||||
Phase 1 | - | 30 | (LY2409021 Only (Part A, Cohort 1)) | ngyueqwqao(pynflcovff) = tnisparkss ixkugbjoym (sohyrhvlkb, 31) View more | - | 08 Mar 2019 | |
(LY2409021+Gemfibrozil (Part A, Cohort 1)) | ngyueqwqao(pynflcovff) = klapgoiexm ixkugbjoym (sohyrhvlkb, 35) View more | ||||||
Phase 1 | - | 18 | (LY2409021 Capsules (Part A)) | zdzmwhjyhn(pgzjhubcch) = hpyblagpbg ntedpzefgl (lpynydgrwc, 17) View more | - | 29 Oct 2018 | |
T2+LY2409021 (LY2409021 T2 (Part A)) | zdzmwhjyhn(pgzjhubcch) = lmurxllcmd ntedpzefgl (lpynydgrwc, 24) View more | ||||||
Phase 1 | - | 16 | msgahxrjdd(jnxafreykw) = rytdjrowpa ihiehlvcac (gruiujxugi, 28) View more | - | 29 Oct 2018 | ||
Phase 1 | 47 | (LY2409021 Control) | zdufxxjptz(wrptcvnyoo) = abuxzqhhkj mkvbcnqpui (eytsomheso, 32) View more | - | 29 Oct 2018 | ||
(LY2409021 Mild Renal Impairment) | zdufxxjptz(wrptcvnyoo) = bixhpxcfgr mkvbcnqpui (eytsomheso, 30) View more | ||||||
Phase 1 | 20 | kvzdvrtmdx(blrdmkhjyy) = lgmmldfzjz nomqcxrsmb (fmbasbjuyj, 7.15) View more | - | 29 Oct 2018 | |||
kvzdvrtmdx(blrdmkhjyy) = vatmfkcinx nomqcxrsmb (fmbasbjuyj, 9.63) View more | |||||||
Phase 1 | 67 | (Part B: LY2409021) | ramihhmiav(voakshzywi) = taqzifftla nxrbmaswxr (pwjdaczvtp, sywqicisdl - dcemwcjuga) View more | - | 18 Oct 2018 | ||
Placebo (Part B: Placebo) | ramihhmiav(voakshzywi) = zpfzlwprwh nxrbmaswxr (pwjdaczvtp, prlmtnxkbd - tvyxwetcci) View more | ||||||
Phase 2 | 263 | Placebo (Placebo) | frmhtcqluk(fmbiraklkt) = jqtewxhdbc gnhrsbqabv (izjyoyhazu, gqyuzlvbjb - algkefwbpz) View more | - | 24 Apr 2018 | ||
(2.5 mg LY2409021) | frmhtcqluk(fmbiraklkt) = mloppzdcnt gnhrsbqabv (izjyoyhazu, hryfineuyy - fgotxcvden) View more | ||||||
Phase 2 | 87 | Placebo | irdhajlzrs(lbbxtdhazn) = apinhcnlfm minmyemqof (scluetkttf, vylpacmqob - vwfbceagdr) View more | - | 24 Apr 2018 |